menu
    • menu
    [{"orgOrder":0,"company":"Versantis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Hematology","graph2":"Preclinical","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Versantis \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Versantis \/ Undisclosed"},{"orgOrder":0,"company":"VarmX","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"VMX-C001","moa":"Factor Xa","graph1":"Hematology","graph2":"Preclinical","graph3":"VarmX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"VarmX \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VarmX \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DISC-0998","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Preclinical","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Rusfertide Analog","moa":"Hepcidin","graph1":"Hematology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Sanofi","sponsor":"Rallybio","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2022","type":"Licensing Agreement","leadProduct":"RLYB-331","moa":"Matriptase-2","graph1":"Hematology","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sanofi \/ Rallybio","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Rallybio"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Jonestrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Jonestrading Institutional Services","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ Jonestrading Institutional Services"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Hematology","graph2":"Preclinical","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kwality Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"INDIA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Hematology","graph2":"Preclinical","graph3":"Kwality Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kwality Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kwality Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"EB003","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Eligo Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eligo Bioscience \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Eligo Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Alveron Pharma","sponsor":"Broadview Ventures","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2024","type":"Financing","leadProduct":"OKL-1111","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Alveron Pharma","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Alveron Pharma \/ Broadview Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Alveron Pharma \/ Broadview Ventures"},{"orgOrder":0,"company":"PK MED","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"PKM-02","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"PK MED","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PK MED \/ Bpifrance","highestDevelopmentStatusID":"4","companyTruncated":"PK MED \/ Bpifrance"},{"orgOrder":0,"company":"Garuda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Garuda Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Garuda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Garuda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Porton Advanced Solutions","sponsor":"DanausGT Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Porton Advanced Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porton Advanced Solutions \/ DanausGT Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Porton Advanced Solutions \/ DanausGT Biotechnology"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":3.6099999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":3.6099999999999999,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Hematology","graph2":"Preclinical","graph3":"Prime Medicine","amount2":3.6099999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hematology","amount2New":3.6099999999999999,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Bristol Myers Squibb","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Bristol Myers Squibb"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : RLYB-331

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Rallybio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi

                            Details : Rallybio plans to prosecute preclinical activities for KY1066/RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $3.0 million

                            May 10, 2022

                            Lead Product(s) : RLYB-331

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Rallybio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kwality Pharmaceuticals

                            India arrow
                            Pharma MES 2025
                            Not Confirmed

                            Kwality Pharmaceuticals

                            India arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Losartan Potassium

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kwality Pharma Gains on Securing RCGM Approval for Erythropoietin

                            Details : Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            January 02, 2025

                            Lead Product(s) : Losartan Potassium

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alveron Pharma

                            Netherlands arrow
                            Pharma MES 2025
                            Not Confirmed

                            Alveron Pharma

                            Netherlands arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKL-1111

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Broadview Ventures

                            Deal Size : $5.2 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Alveron Secures €5M Seed Extension Financing for Intracranial Hemorrhage Therapy

                            Details : The financing aims to advance the development of its innovative drug, OKL-1111, for the treatment of intracranial haemorrhage.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 06, 2024

                            Lead Product(s) : OKL-1111

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Broadview Ventures

                            Deal Size : $5.2 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Prime Medicine

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BMS Pays Prime $110M to Form T-cell Therapy Pact

                            Details : Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $110.0 million

                            September 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Prime Medicine

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Prime Medicine

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Prime Medicine and Bristol Myers Partner On Ex Vivo T-Cell Therapies

                            Details : The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 30, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $3,610.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PK MED

                            France arrow
                            Pharma MES 2025
                            Not Confirmed

                            PK MED

                            France arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PKM-02

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $1.6 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            PK MED Receives €1.5M DeepTech Financing from Bpifrance for Cell-Homing Implant

                            Details : The funding will accelerate the company’s PKM-02, an innovative technology aiming to enhance bone marrow transplantation in several diseases with high unmet medical need such as hemoglobinopathies.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 24, 2024

                            Lead Product(s) : PKM-02

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Bpifrance

                            Deal Size : $1.6 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Porton Advanced Solutions

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Porton Advanced Solutions

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Engineering

                            Details : This collaboration will accelerate the development of innovative therapeutics for the treatment of some diseases such as blood, skin, and liver-related diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : DanausGT Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Garuda Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Garuda Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $62.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Fly Like an Eagle: Garuda Brings in A $62M Series B

                            Details : The Series B funds will funnel into two programs Blood stem cell-based therapy, slated to hit the clinic in 2024 - transfusion-dependent beta-thalassemia (TDBT) in Europe and bone marrow failure syndrome in Europe, South America and North America

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 07, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $62.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Disc medicine

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Disc medicine

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DISC-0998

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Disc Medicine Announces Multiple Presentations Across Hematology Portfolio at the 64th American Society of Hem...

                            Details : DISC-0998 is an investigational anti-HJV mAb with an engineered Q and L mutation (QL-mutation) in the Fc region, aimed to alter binding to the FcRn receptor, resulting in an increased PK half-life.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 03, 2022

                            Lead Product(s) : DISC-0998

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Protagonist Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed

                            Protagonist Therapeutics

                            U.S.A arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rusfertide Analog

                            Therapeutic Area : Hematology

                            Study Phase : Preclinical

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meet...

                            Details : Rusfertide Analog-PN23114 as a Hepcidin Mimetic Provides Efficacy Benefits in Conjunction with Phlebotomy in Mouse Model for Hereditary Hemochromatosis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            November 03, 2022

                            Lead Product(s) : Rusfertide Analog

                            Therapeutic Area : Hematology

                            Highest Development Status : Preclinical

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth